AnelloVector

AnelloVector is a novel class of viral vector developed by Ring Therapeutics for gene and nucleic acid therapy. Based on commensal human anelloviruses, these vectors are engineered to deliver diverse therapeutic payloads—including single- or double-stranded DNA and RNA—across multiple tissue types. The platform leverages the natural immune stealth and tissue tropism of anelloviruses, enabling redosability (repeat dosing) without the immunogenicity limitations seen with adeno-associated virus (AAV) vectors. The technology is enabled by Ring’s proprietary in vitro assembly system (AnelloBricks), which uses recombinant capsid proteins to encapsulate nucleic acid payloads efficiently and at scale. Preclinical studies have demonstrated durable gene expression in vivo for up to 12 months post-administration, as well as successful delivery in both rodent and non-human primate models. The versatility of the platform allows for broad application across genetic disorders, ophthalmology, oncology, metabolic diseases, hematology, CNS disorders, and inflammatory diseases[1][2][4][5][6][7][8][9][10].

Brand names

AnelloVector

Other names

Anellovectoranellovirus vector